Skip to main content
eScholarship
Open Access Publications from the University of California

UC San Diego

UC San Diego Electronic Theses and Dissertations bannerUC San Diego

Study of Gut Pathobiont, Bacteroides vulgatus, in Inflammatory Bowel Disease: From Discovery to Therapeutic Development

Abstract

Gut commensals are known to play vital roles in homeostasis within the gastrointestinal tract. Among the resident microbes, Bacteroides vulgatus has shown distinct abundance and molecular signatures in gastrointestinal diseases such as inflammatory bowel disease (IBD). As a resident member of the gastrointestinal tract and having a prevalent presence within the large intestine, B. vulgatus is among the glycan-degrading bacterial families aiding important functions integral for host nutrient acquisition and secondary protection against external pathogens, to name a few. Importantly, previous research has identified proteolysis capabilities by B. vulgatus to be significantly correlated to active ulcerative colitis (UC)- a subtype of IBD. However, publicly available reference proteomes for B. vulgatus remain vastly understudied, with only 6.6% of the predicted proteomes currently experimentally validated. The first chapter of this dissertation provides a breath of the advancements made through different -omic technology aiding the understanding of gut commensals such as B. vulgatus and how application of mass spectrometry-based proteomics is a promising tool for the exploration of the underexplored gut proteome.In the second chapter of this dissertation, we prove the efficacy of mass spectrometry-based proteomics in filling in this knowledge gap by creating the first-of-a-kind proteome atlas for B. vulgatus under IBD-related stress conditions. In doing so, we identified proteins of previously unknown function relevant to host immune responses. Through biochemical approaches, we validate the use of this technique to study gut commensal proteomes.In the third chapter, we apply mass spectrometry-based proteomics to identify and validate the impact and function of proteolytic proteins relevant to UC. Mining our previously published dataset from UC patients with varying degrees of active disease, we identified three proteolytic targets that we hypothesize may be driving UC-relevant proteolysis: dipeptidyl peptidase-4 (DPP-4), dipeptidyl peptidase-7 (DPP-7), and aminopeptidase C (Ac). Through molecular genetic approaches, we selectively deleted genes encoding Dpp-4 (BVU_1094), Dpp-7 (BVU_2253), and Ac (BVU_2072) to generate a triple mutant strain. Using the triple mutant strain, we validated that the depletion of proteolytic capacity of B. vulgatus led to differential responses in simple and complex systems. In the in vitro model of the colonic barriers, the Caco-2 monolayer model, we identify the relevance of DPP-4, DPP-7, and Ac for barrier integrity, with reduced barrier leakage observed in monolayers cultured with the triple mutant strain. Confocal microscopy of these monolayers surveying tight junction proteins, ZO-1 and occludin, shows a negative impact on monolayer tight junctions in response to B. vulgatus wild-type. Monocolonization with either B. vulgatus wild-type or with the triple mutant strain shows a clear difference in colon inflammation, with reduced colitis in mice colonized with the triple mutant strain. Further, proteomic analysis of colon and fecal samples shows clear differences in inflammatory pathways in response to the triple mutant strain supporting lipocalin-2 reductions (Lcn-2). Finally, we applied multiplex substrate profiling by mass spectrometry on recombinantly expressed DPP-4, DPP-7, and Ac, where we show the amino acid sequence specificity for each protease, aiding the generation of enzyme-specific substrates for downstream validation in acquiring enzyme-specific inhibitors. Herein, we show the power of mass spectrometry-based proteomics for the study of idiopathic diseases through a gut microbial lens, which facilitated the identification of bacterial-centric therapeutic targets for the treatment of ulcerative colitis.

Main Content

This item is under embargo until September 11, 2027.